Day: September 3, 2020

iBusiness Group Network has released a first of its kind cash and credit access system which provides business owners easy access to financing options of all kinds for their businesses. The Business Finance Suite has thousands of financing sources, and more access to money than any other stand-alone system in the world. The finance suite also provides the access to the largest supply of financial products that are available today. “Access to money has always been one of the biggest challenges a business owner faces,” Shelia Eggleston, CEO of iBusiness Group Network. “Through the Finance Suite, entrepreneurs can quickly access the cash and credit they need to grow their business.” The Business Finance Suite provides unprecedented access to money and capital for business owners. Virtually every type of known legitimate financing source is...

The entire world is fighting a pandemic and it has made us realize the importance of healthcare in the country. Every medical professional contributes to the healthcare industry in the country and the Government is trying its best to make it easier for medical experts to expand their practice. If you are a medical expert, you will agree to the fact that new equipment does not come cheap and in order to replace the equipment, you need access to funds. You can apply for a hospital equipment loan at Hero FinCorp. Considered as one of the most reliable and sought after service provider, Hero FinCorp has several loan products to choose from. The medical equipment loan is available for the purchase of new or refurbished equipment and the application process is quick and hassle free. If you have the education and experience, you can apply for...

Recently, Indian GDP for June 2020 Quarter printed -23.9% growth. Interestingly, just a few weeks before this print, RBI Monetary Policy Committee announced that it was holding rates steady because Consumer Price Index (CPI) inflation was at 6.93%, outside the target range of 2% to 6%. Mr. Dhuri in his recently published article titled “Guiding policymaking through the fog of Covid19 induced lockdowns” questions the underlying logic of keeping the interest rates steady while we have strong degrowth, disrupted supply, and non-demand driven inflation in the economy. He also talks about how the Taylor rule of monetary policy can be used as a guide in this scenario. Running the numbers using the Taylor rule presents us with some interesting finding for the March 2021 policy rates and highlights the fact that India may need a 250 basis points...

POSEIDON – Implants in Canada continue; interim results expected H1 2021RED DESERT – Implants continue; interim results expected Q4 2020DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and EuropeContinued growth in European commercial implantsSecured additional funding extending cash runway into H2 2021Conference call with live webcast presentation today at 14:00 CEST / 08:00 am ESTGHENT, Belgium, Sept. 03, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial results for the six-month period ending 30 June 2020 and its outlook for the remainder of the year and into 2021.Ian Crosbie, Chief Executive Officer...

                                            Company announces Notice of Results for the six months ended June 30, 2020Amsterdam, The Netherlands, September 3, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell-based medicines for life-threatening diseases, announces its investor events for September 2020.Interim resultsKiadis will be issuing its interim results for the six months ended June 30, 2020 at 7:00 CEST / 6:00 BST / 1:00 EDT on Wednesday, September 30, 2020.Kiadis’ management will host a webcast and conference call for analysts on Wednesday, September 30, 2020 at 15:00 CEST / 14:00 BST / 9:00 EDT. A copy of the announcement will be made available on the Kiadis website and details of the webcast and conference call...

Media relations:Florence LièvreTel.: +33 1 47 54 50 71florence.lievre@capgemini.comInvestor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com  First half performance reflects the Group’s resilience  Revenues of €7,581 million, up +8.2% with the acquisition of AltranH1 constant currency growth of +7.9% and organic growth* of -3.4%Q2 constant currency growth of +13.4% and organic growth* of -7.7%Operating margin*up +3% in value and down a limited -0.6 points to 10.8% of revenuesNormalized earnings per share*down -4% and Net profit (Group share) down -20%Organic free cash flow*up €16 million to €106 millionParis, September 3, 2020 – The Board of Directors of Capgemini SE, chaired by Paul Hermelin, convened on September 2, 2020 to review the accounts1 of Capgemini Group for the first half of 2020.Aiman Ezzat, Chief...

Relations presse :Florence LièvreTél. : 01 47 54 50 71florence.lievre@capgemini.comRelations Investisseurs :Vincent BiraudTél. : 01 47 54 50 87vincent.biraud@capgemini.comLa performance au 1er semestre témoignede la résilience du GroupeChiffre d’affaires de 7 581 millions d’euros, en hausse de +8,2% avec l’acquisition d’AltranCroissance de +7,9% à taux de change constants et de -3,4% en organique*sur le 1er semestreCroissance de +13,4% à taux de change constants et de -7,7% en organique*sur le 2ème trimestreMarge opérationnelle*en hausse de +3% en valeur et en retrait limité de -0,6 point en taux, soit 10,8%Recul de -4% du résultat normalisé par action*et de -20% du résultat net part du GroupeFree cash-flow organique* en hausse de 16 millions d’euros à 106 millions d’eurosParis, le 3 septembre 2020 – Réuni à Paris le 2 septembre 2020...

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA, SOUTH AFRICA OR SWITZERLANDPress ReleaseRegulated Information – Inside information3 September 2020, 7:00am, Antwerp (Berchem), Belgium: VGP NV (‘VGP’ or ‘the Group’), a leading European provider of high-quality logistics and semi-industrial real estate, announces today that VGP Belgium NV (a 100% subsidiary of VGP NV and formerly named VGP MISV Comm.VA) successfully placed 929,153 existing ordinary shares in VGP (the “Shares”), corresponding to 4.51% of the outstanding share capital of VGP, by means of a private placement via an accelerated bookbuild offering to international institutional investors (the ‘Placement’). The Shares were placed at a price of €117.50 per Share, resulting in €109.18 million in gross proceeds. The price represents...

NIET VOOR DISTRIBUTIE IN OF NAAR DE VERENIGDE STATENVAN AMERIKA, JAPAN, CANADA, AUSTRALIË, ZUID-AFRIKA OF ZWITSERLANDPersberichtGereglementeerde informatie – Voorkennis3 september 2020, 07:00u, Antwerpen (Berchem), België: VGP NV (‘VGP’ of ‘de Groep’), een toonaangevende Europese ontwikkelaar van hoogwaardig logistiek en semi-industrieel vastgoed, kondigt vandaag aan dat VGP Belgium NV (een 100% dochteronderneming van VGP NV en voorheen genaamd VGP MISV Comm.VA) met succes 929.153 bestaande aandelen in VGP (de ”Aandelen”) heeft geplaatst, wat overeenkomt met 4,51% van het uitstaande aandelenkapitaal van VGP, door middel van een versnelde private plaatsing (accelerated bookbuild) bij institutionele investeerders (de “Plaatsing”). De aandelen waren geplaatst aan een prijs van €117,50 per Aandeel, wat resulteert in...

PRESS RELEASE: REGULATED INFORMATION3 September 2020, 07:00 CEST            BIOCARTIS ANNOUNCES H1 2020 RESULTSMechelen, Belgium, 3 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its business highlights and financial results for the first half of 2020, prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as adopted by the European Union. Furthermore, the Company reinstates its outlook for the full year 2020.Commenting on the H1 2020 results, Herman Verrelst, Chief Executive Officer of Biocartis, reacted: “The global pandemic definitely left its marks, but we nevertheless delivered a 12% growth of overall commercial cartridge volumes in H1 2020. Supported by a loyal customer base and a swift recovery towards the end...